Jelle Thole

Jelle Thole

Director Biological Products for Human Use

Biofabri SLU, Spain

Tel: +34 986 330 400






Member of Scientific Advisory Board, Network Affiliate


Research Keywords: 

TB, product and clinical development



Dr Jelle Thole is Director of Biological Products for Human Use, Biofabri, a human vaccine development and manufacturing company in Porrino, Spain. He is the Founder and former Director of TuBerculosis Vaccine Initiative (TBVI), a not for profit foundation supporting the development new vaccines against tuberculosis based in Lelystad, The Netherlands. He has coordinated several large integrated EC projects (TBVAC, NEWTBVAC), aiming to develop new vaccines against tuberculosis. Jelle Thole is member of the Scientific Advisory Board (SAB) of the VALIDATE Network and member of the Board of Division of Vaccinology of the Royal Dutch Society for Microbiology, The Netherlands. Jelle Thole is author of over 70 publications on antigen discovery, host-pathogen interactions, and immunology of human and veterinary mycobacterial pathogens including tuberculosis, paratuberculosis and leprosy.


Related Websites: 


Key Publications:

  1. Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, Ho MM, Mayner RE, Thole J, Walker KB, Liu M, Lambert PH. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine. 2005 May 31;23(29):3753-61.
  2. Brennan MJ, Thole J. 2012. Tuberculosis vaccines: a strategic blueprint for the next decade. Tuberculosis 92: Suppl 1:S6-13.
  3. Evans TG, Brennan, MJ, Barker, L and J. Thole. 2013. Preventive vaccines for tuberculosis. Vaccine 31S: B223–B226.
  4. Dutruel C, Thole J, Geels M, Mollenkopf HJ, Ottenhoff T, Guzman, CA, Fletcher HA,Leroy O, Kaufmann SH. 2014. TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: 'how can big data help? Vaccine 32: 4365-8.